Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Stephen Johnston(Royal Marsden NHS Foundation Trust), Masakazu Toi(Kyoto University), Joyce O’Shaughnessy(Texas Oncology), Priya Rastogi(NSABP Foundation), Mario Campone(Institut de Cancérologie de l'Ouest), Patrick Neven(Universitair Ziekenhuis Leuven), Chiun‐Sheng Huang(National Taiwan University Hospital), Jens Huober(University of St. Gallen), Georgina Garnica Jaliffe, İrfan Çiçin(Trakya University), Sara M. Tolaney(Dana-Farber Cancer Institute), Matthew P. Goetz(Mayo Clinic in Arizona), Hope S. Rugo(University of California, San Francisco), Elżbieta Senkus(Gdańsk Medical University), Laura Testa(D’Or Institute for Research and Education), Lucia Del Mastro(Ospedale Policlinico San Martino), Chikako Shimizu(National Center for Global Health and Medicine), Ran Wei(Eli Lilly (United States)), Ashwin Shahir(Loxo Oncology at Lilly (United States)), Marı́a Jesús Muñoz(Loxo Oncology at Lilly (United States)), Belén San Antonio(Loxo Oncology at Lilly (United States)), Valérie André(Eli Lilly (United States)), Nadia Harbeck(Ludwig-Maximilians-Universität München), Miguel Martín(Hospital General Universitario Gregorio Marañón)
Cited by 550Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis